Revance Therapeutics reported $378.38M in Loan Capital for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
Bristol Myers Squibb BMY:US $ 37107M 343M
Cara Therapeutics CARA:US $ 0 0
Eli Lilly And LLY:US $ 14692M 460.9M
Horizon Pharma HZNP:US $ 2550.99M 1.75M
JAZZ PHA JAZZ:US $ 5990M 2.87M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Pacira Pharmaceuticals PCRX:US $ 721.88M 7.86M
Procter & Gamble PG:US $ 22848M 919M
Revance Therapeutics RVNC:US $ 378.38M 52.48M
Supernus Pharmaceuticals SUPN:US $ 0M 400.38M
Teva Pharmaceutical Industries TEVA:US $ 20363M 477M